Product Description: Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells[1].
Applications: COVID-19-immunoregulation
Formula: N/A
References: [1]Andrew M. Brunner, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood (2020) 136 (Supplement 1): 1–2.
CAS Number: 2252262-24-9
Molecular Weight: N/A
Compound Purity: 99.14
Research Area: Inflammation/Immunology
Solubility: H2O
Target: Tim3